- COVID-19 with Mycoplasma pneumoniae coinfection appears to be associated with increased thrombosis risk.
- Coinfection was not associated with an increase in major complaints at admission.
Why this matters
- Close monitoring, routine anticoagulation prophylactics are indicated.
- Of 874 patients, 2.5% had coinfection.
- Among 88 COVID-19-only patients in matched comparator group, median age was 57 years.
- Among the 22 with coinfection, median age was 56.5 years.
- Major complaints at admission, overall: fever (59.1%), cough (28.2%), dyspnea (8.2%), fatigue (9.1%), diarrhea (3.6%).
- Rheumatoid arthritis was present only in the coinfection group (9.1% vs 0.0% in COVID-only group; P=.05).
- Vs patients with COVID-19 only, patients with coinfection had, on average (±standard deviation):
- Higher bilirubin levels: 14.67±28.72 vs 8.03±4.07 (P=.037).
- Shorter prothrombin time: 11.60±0.84 vs 13.34±5.4 (P=.004).
- Higher prothrombin activity: 104.90±20.14 vs 89.78±30.65 (P=.006).
- Different antibiotic, corticosteroid strategies had no effect on outcomes.
- Mortality: 1 patient with coinfection (4.5%) vs 2 (2.3%) with COVID-19 only (P=1.00).
- Patients with coinfection also had longer cough duration: 20 vs 16.25 days (P=.043).
- Retrospective, observational analysis of morbidity, other clinical outcomes of Chinese patients.
- Funding: Anhui Provincial Special Project.
- Retrospective, observational.
- Small sample.
- Possible false negatives.
- Selection bias.